Skip to main content
SpringerLink
Log in

Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout

  • Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

We aimed to investigate the effects of febuxostat on IR and the expression of high-sensitivity C-reactive protein (hs-CRP) in patients with primary gout. Forty-two cases of primary gout patients without uric acid-lowering therapy were included in this study. After a physical examination, 20 age- and sex-matched patients were included as normal controls. The levels of fasting insulin (INS), fasting blood glucose (FBG), and hs-CRP were determined. IR was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Gout patients had higher levels of UA, INS, HOMA-IR, and hs-CRP than normal controls (P < 0.05). After 4-, 12-, and 24-week febuxostat treatments, UA and hs-CRP concentrations were significantly lower than baseline (P < 0.05). INS and HOM-IR decreased slightly after a 4-week treatment with febuxostat but declined significantly after 12 and 24 weeks of treatment. Importantly, hs-CRP values positively correlated with those of HOMA-IR (r = 0.353, P = 0.018) and INS (r = 0.426, P = 0.034). Our findings confirm that IR exists in gout patients and implicate that febuxostat can effectively control the level of serum UA and increase insulin sensitivity in primary gout patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Roddy E, Choi HK (2014) Epidemiology of gout. Rheum Dis Clin North Am 40:155–175

    Article  PubMed  PubMed Central  Google Scholar 

  2. Li C, Hsieh MC, Chang SJ (2013) Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol 25:210–216

    Article  CAS  PubMed  Google Scholar 

  3. Paneni F, Costantino S, Cosentino F (2014) Insulin resistance, diabetes, and cardiovascular risk. Curr Atheroscler Rep 16:419

    Article  PubMed  Google Scholar 

  4. Reaven GM (2011) Insulin resistance: from bit player to centre stage. CMAJ 183:536–537

    Article  PubMed  PubMed Central  Google Scholar 

  5. Viazzi F, Leoncini G, Pontremoli R (2011) Cardiovascular and renal effects of hyperuricemia and gout. Reumatismo 63:253–262

    CAS  Google Scholar 

  6. Shah A, Keenan RT (2010) Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep 12:118–124

    Article  PubMed  Google Scholar 

  7. Puig JG, Martinez MA (2008) Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 20:187–191

    Article  CAS  PubMed  Google Scholar 

  8. Frampton JE (2015) Febuxostat: a review of its use in the treatment of hyperuricemia in patients with gout. Drugs 75:427–438

    Article  CAS  PubMed  Google Scholar 

  9. Mayans L (2015) Metabolic syndrome: insulin resistance and prediabetes. FP Essent 435:11–16

    PubMed  Google Scholar 

  10. Chou P, Lin KC, Lin HY, Tsai ST (2001) Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. J Rheumatol 28:571–576

    CAS  PubMed  Google Scholar 

  11. Chen L, Chen R, Wang H, Liang F (2015) Mechanisms linking inflammation to insulin resistance. Int J Endocrinol 2015:508409

    PubMed  PubMed Central  Google Scholar 

  12. Chahwala V, Arora R (2009) Cardiovascular manifestations of insulin resistance. Am J Ther 16:e14–e28

    Article  PubMed  Google Scholar 

  13. Razani B, Chakravarthy MV, Semenkovich CF (2008) Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 37:603–621

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H (1999) Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22:818–822

    Article  CAS  PubMed  Google Scholar 

  15. Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL (2014) Assessment of pancreatic beta-cell function: review of methods and clinical applications. Curr Diabetes Rev 10:2–42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Borghi C (2015) The role of uric acid in the development of cardiovascular disease. Curr Med Res Opin 31(Suppl 2):1–2

    Article  PubMed  Google Scholar 

  17. Abeles AM (2015) Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep 17:13

    Article  PubMed  Google Scholar 

  18. Borghi C, Verardi FM, Pareo I, Bentivenga C, Cicero AF (2014) Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther 12:1219–1225

    Article  CAS  PubMed  Google Scholar 

  19. Ndumele CE, Pradhan AD, Ridker PM (2006) Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr 1:190–196

    Article  PubMed  Google Scholar 

  20. Saito I, Maruyama K, Eguchi E (2014) C-reactive protein and cardiovascular disease in East asians: a systematic review. Clin Med Insights Cardiol 8:35–42

    PubMed  Google Scholar 

  21. Perez-Ruiz F, Becker MA (2015) Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin 31(Suppl 2):9–14

    Article  PubMed  Google Scholar 

  22. Krishnan E (2010) Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 49:1229–1238

    Article  CAS  Google Scholar 

  23. Meotti FC, Jameson GN, Turner R, Harwood DT, Stockwell S, Rees MD, Thomas SR, Kettle AJ (2011) Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation. J Biol Chem 286:12901–12911

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Yu S, Ren Q, Wu W (2015) Effects of losartan on expression of monocyte chemoattractant protein-1 (MCP-1) in hyperuricemic nephropathy rats. J Recept Signal Transduct Res 35:458–461

    Article  CAS  PubMed  Google Scholar 

  25. Umekawa T, Chegini N, Khan SR (2003) Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 18:664–669

    Article  CAS  PubMed  Google Scholar 

  26. Nomura J, Busso N, Ives A, Tsujimoto S, Tamura M, So A, Yamanaka Y (2013) Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. PLoS ONE 8:e75527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Fukui T, Maruyama M, Yamauchi K, Yoshitaka S, Yasuda T, Abe Y (2015) Effects of febuxostat on oxidative stress. Clin Ther 37:1396–1401

    Article  CAS  PubMed  Google Scholar 

  28. Bridgeman MB, Chavez B (2015) Febuxostat for the treatment of gout. Expert Opin Pharmacother 16:395–398

    CAS  PubMed  Google Scholar 

  29. Saviola G, Benucci M, Abdi-Ali L, Sacco S, Cera I, Rossini M (2014) Can febuxostat reduce triglyceride and cholesterol serum levels in gouty patients? J Clin Rheumatol 20:394–395

    PubMed  Google Scholar 

  30. Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, Hata H, Shiono M (2015) Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). J Cardiol 66:298–303

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Rheumatology and Immunology, Beijing Chao-Yang Hospital, Capital Medical University, 8 GongrenTiyuchangNanlu, Chaoyang District, Beijing, 100020, China

      Juan Meng, Xiaoxu Yuan & Yuewu Lu

    2. Department of Nephrology, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China

      Yanchun Li

    Authors
    1. Juan Meng
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Yanchun Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Xiaoxu Yuan
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Yuewu Lu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Yuewu Lu.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Ethical approval

    The study was approved by the ethics committees of the participating hospitals and institutes. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

    Informed consent

    Informed consent was obtained from all individual participants included in the study.

    Additional information

    Juan Meng and Yanchun Li have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Meng, J., Li, Y., Yuan, X. et al. Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. Rheumatol Int 37, 299–303 (2017). https://doi.org/10.1007/s00296-016-3612-2

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00296-016-3612-2

    Keywords

    Search

    Navigation